Cancer is not new. It has plagued humanity for generations and cut short far too many lives. But our understanding of it is also ever-evolving. Through seeds sown out of despair, we have embarked on a journey filled with innovation and determination.
Enigma Cancer Therapeutics is the brainchild of over 100 years of combined experience in understanding how cancer affects the body. ECT is dedicated to pushing boundaries in oncology research, application and treatment; paving the way for increased survival rates, longer lives and enhanced patient outcomes. We’ve engineered a world-first that capitalises on and promotes the body’s own natural defence system to realign the odds in the fight against cancer.
Uncover the power of cutting-edge understanding, technology and methods combined with unwavering passion to combat and actively block tumour growth, whilst also ‘warming’ these tumours up and helping reignite hope in the face of a previously poor prognosis.
Together, we’re striving for a future where survival rates soar and precious time is extended. To achieve this, we’ve put together a world-class team from every corner of the globe…
About Us
Our Management Team
-
Patrick Hextall
CHIEF MANUFACTURING OFFICER
-
Berni Hambleton
CHIEF EXECUTIVE OFFICER
-
Brian Champion
CHIEF SCIENCE OFFICER
Scientific Advisory Board
-
Prof. B. Lindmark
(Pharma/Biotech RnD)
-
Dr. N. Barton
(Brain Cancer + RnD)
-
Dr. T. Hermiston
(Pharma/Biotech RnD)
-
Prof. D. Fennell
(Mesothelioma Clinical Research)
-
Dr. M. McHale
(Pharma/Biotech RnD)
-
Dr. D. Humphreys
(Antibody Engineering)
